Novonesis Plant Biosolutions A/S

CVR: 30919246

Declining 12% p.a.Medium companyWell-established (18 yrs)Profitable

Secondary names: NOVOZYMES BIOLOGICALS HOLDING A/S, Novozymes BioAg A/S

Active

The financial health of Novonesis Plant Biosolutions A/S appears robust, with a significant profit of 403,926,577 DKK in 2024, up from 309,011,928 DKK in 2023. Revenue has shown a stable trend, increasing from 112,486,821 DKK in 2023 to 116,711,457 DKK in 2024, although it has declined from a peak of 148,562,040,000 DKK in 2022. The company's equity position remains strong at 733,197,785 DKK, indicating a solid foundation despite fluctuations in revenue. While the profit margins have improved notably, the substantial drop in revenue from 2022 raises concerns about long-term sustainability within the intellectual property leasing industry. Overall, Novonesis is well-positioned, but it must address revenue volatility to maintain its competitive edge.

AI-generated summary

Overview

Company type: A/S; Aktieselskab
Address: Biologiens Vej 2, 2800 Kongens Lyngby; LYNGBY-TAARBÆK; 2800 Kongens Lyngby; Find nearby companies
Founded: 22.10.2007

Details

Industry: Leasing af intellektuelle ejendomsrettigheder og lignende produkter, dog ikke ophavsretsbeskyttede værker; Code: 774000
Capital: 600.000 kr.

Purpose

Selskabets formål er drift af og investering i forskning, udvikling, produktion og handel med biologiske løsninger, herunder bioteknologiske produkter og processer samt at drive virksomhed, der efter bestyrelsens nærmere bestemmelse står i forbindelse hermed. Selskabet tilstræber at drive sin virksomhed på bæredygtig og ansvarlig vis, herunder i økonomisk, miljømæssig og social henseende.